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3466ABSTRACT
Background. Solid organ transplant recipients have an increased cancer risk owing to
immunosuppression and oncogenic viral infections. We report on the incidence and types
of bladder cancer in kidney transplant recipients in Ireland, describing possible additional
risk factors and outcomes in these patients.
Methods. We identified kidney transplant recipients diagnosed with de novo bladder
cancer between January 1, 1994, and July 31, 2012, by integrating data from the Irish
National Cancer Registry and National Renal Transplant Registry. We calculated the
standardized incidence ratio (SIR) and examined patient and tumor characteristics and
1-year survival rate.
Results. Fifteen patients were diagnosed with de novo bladder cancer during the study
period, representing 0.48% of kidney transplant recipients. The SIR was 2.5 (95% CI,
1.4e4.2; P < .001). The mean interval between transplantation and diagnosis of bladder
tumor was 8.6 years and mean age at time of diagnosis was 55.7 years. Sixty percent of
patients were male. The tumor types were transitional cell carcinoma (9 patients),
squamous cell carcinoma (3 patients), adenocarcinoma (1 patient), carcinoma in situ (1
patient), and diffuse large B-cell lymphoma (1 patient). Beside immunosuppression, risk
factors associated with bladder cancer were urogenital disease (6 patients), cyclophos-
phamide exposure (2 patients), BK nephropathy (1 patient), analgesic nephropathy (1
patient), and extensive smoking (1 patient). Eight patients underwent radical cystectomy
for invasive tumors, with resection of other pelvic organs in 7 patients. Mortality rate within
the first year was 40%.
Conclusion. Bladder cancer occurred more commonly in kidney transplant recipients
with a predominance of aggressive tumors and a high mortality. In patients with preexisting
risk factors such as urologic abnormalities and cyclophosphamide exposure careful
assessment before transplantation and vigilant monitoring posttransplantation with a low
threshold for cystoscopy may improve outcomes.*Address correspondence to Samar Medani, Department of
Nephrology, Beaumont Hospital, Beaumont Road, Dublin 9,
Republic of Ireland. E-mail: smedani@doctors.org.ukMALIGNANCY IS CURRENTLY a leading cause ofdeath with a functioning graft in solid organ
transplant recipients [1,2]. Although it is recognized that
immunosuppressive therapy and oncogenic viral infections
may confer an increased cancer risk in these patients, little is
known about the effects of interaction between these factors
and other inherent or environmentally acquired risk de-
terminants of cancer development. Optimal screening stra-
tegies for cancer in the setting of solid organ transplantation
based on these baseline risks are continuously evolving.4
.org/10.1016/j.transproceed.2014.06.075There is limited literature relating to pretransplant and
posttransplant screening for bladder cancer in solid organ
transplant candidates or recipients who have preexisting
identifiable risk factors, such as exposure to cyclophospha-
mide, and the data to substantiate recommendations for suchª 2014 by Elsevier Inc. All rights reserved.
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BLADDER CANCER IN RENAL ALLOGRAFT RECIPIENTS 3467screening are scarce. The Canadian Society of Trans-
plantation consensus guidelines published in 2005 and a draft
guideline published in 2011 on the Caring for Australians
with Renal Impairment (CARI) website recommend that
pretransplant cystoscopic surveillance be considered for
those with analgesic nephropathy and those who have
received cyclophosphamide therapy [3,4]. These recom-
mendations are based on the clinical practice guidelines for
the evaluation of renal transplantation candidates published
in the American Journal of Transplantation in 2001 [5].
However, the 2009 Kidney Disease: Improving Global Out-
comes guideline for the care of kidney transplant recipients
did not replicate this recommendation. There is even less
guidance on the posttransplantation screening of patients
with additional risk factors for bladder malignancy with no
prospective data supporting the cost effectiveness of any
screening strategies. Experts in the field have again recom-
mended urologic examination in patients who develop de
novo microhematuria and have a history of analgesic
nephropathy or those who received cyclophosphamide
especially if the cumulative dose is >20 g [6]. To date, there
are few reports on posttransplantation bladder cancer in the
setting of prior cyclophosphamide therapy [7e9] or analgesic
nephropathy [10]. Other factors that can potentiate the risk
have been less well-defined.
We sought to examine the incidence and risk associations
of bladder cancer occurring after renal transplantation in
the Irish population, and to raise suggestions for enhanced
patient screening in the pretransplantation and post-
transplantation course to avoid delays in diagnosis and
optimize survival potential.METHODS
This retrospective, registry-based study looked at bladder cancer
incidence among renal transplant recipients (RTRs) in comparison
with the entire Irish population. Patients were identified by
computerized matching of the Irish National Cancer Registry
(NCRI) and the National Renal Transplant registry (NRTR) da-
tabases. The medical records and histological reports of patients
were accessed for clinical data. The NCRI is a nationwide register
of cancers since January 1994. The NRTR includes renal trans-
plants carried out in Ireland since 1964. The study population
comprised all patients who underwent kidney transplantation in
Ireland from 1964 through July 31, 2012, and who had not died
before January 1, 1994. The time at risk was therefore defined as
the time from the first transplant or January 1, 1994, if the first
transplant occurred before this date, until death of the patient or
July 31, 2012, regardless of transplantation outcomes. Only records
of first primary bladder cancers that were diagnosed after renal
transplantation were included. Patients who were transplanted
abroad or subsequently followed up abroad (lost to follow-up) were
excluded. We compared the incidence with respect to the general
population by calculating the age and gender adjusted standardized
incidence ratio (SIR). The SIR was calculated by dividing the actual
bladder cancer incidence by the expected cancer rate in the trans-
plant population. Multiplying the person years at risk for kidney
transplant patients by the average of gender-specific and age-
groupespecific yearly cancer incidence rates in the entire populationgives the expected cancer rate in the transplant population. The risk
of bladder cancer with time after renal transplantation and survival
after diagnosis of bladder cancer were evaluated by KaplaneMeier
survival analyses. Statistical analyses were performed with the SPSS
software package (SPSS< Inc., Chicago, IL).RESULTS
Between 1964 and July 31, 2012, 3141 patients underwent
3688 renal transplantations in Ireland, excluding 377
patients who died before 1994, 29 patients who were
transplanted abroad and 24 patients who were lost to
follow-up. Mean age at the time of first kidney transplant
was 41.9  16.3 years; 63% of recipients were male. There
were 15 renal allograft recipients with a de novo malignant
bladder tumor diagnosed during the study period, 60% of
whom were male. Mean age at time of diagnosis of bladder
tumor was 55.7 years and mean interval between trans-
plantation and diagnosis of bladder tumor was 8.6 years.
The SIR for malignant bladder tumors in kidney transplant
recipients was 2.5 (95% CI, 1.4e4.2; P < .001).
Table 1 illustrates the patient and tumor characteristics of
the identified cases. The time interval between trans-
plantation and diagnosis, treatment received, and survival
after diagnosis for each patient are also shown. Transitional
cell carcinoma (papillary or invasive urothelial carcinoma)
was the commonest tumor type. One third of patients had
nonurothelial tumors, including squamous cell carcinoma,
adenocarcinoma, and diffuse large B-cell lymphoma. In 11
of the 15 patients (73.3%), an additional risk factor asso-
ciated with bladder malignancy besides immunosuppression
was identified. In 6 patients (40%), the additional risk was
attributed to a genitourinary condition or a congenital
anomaly associated with increased bladder cancer risk. Prior
cyclophosphamide therapy, BK nephropathy, analgesic
nephropathy, and extensive smoking were other risk asso-
ciations seen in this cohort. There were 2 patients who
received cyclophosphamide 1 year before transplantation.
These additional risk factors are demonstrated in Table 2.
Eight patients were treated with radical cystectomy for
invasive tumors; 7 of these had aggressive disease necessi-
tating resection of other pelvic organs. Five out of 6 female
patients had aggressive tumors and required invasive sur-
gery. Five out of the 9 male patients also had aggressive
tumors with a high mortality (80% at 1 year). Overall
mortality rate within the first year was 40%. In 5 of the 6
patients who died within the first year of bladder cancer
diagnosis, death was owing to tumor-related complications,
including neutropenic sepsis, pulmonary embolism, and
progression of metastatic disease.
Figure 1 shows the cumulative risk of bladder cancer in
RTRs. At 15 years posttransplantation, an estimated 0.9%
of our renal transplant population will develop bladder
cancer with an incidence rate of 5.6 events per 10,000
patient-years. Estimated survival after diagnosis of bladder
cancer is shown in Fig 2, predicting 1- and 5-year survivals of
60% and 36%, respectively.
Table 1. Patient and Tumor Characteristics, Treatment, and Outcomes of Bladder Cancer in Renal Transplant Recipients
Patient








Diagnosis (y) Gender Etiology of ESKD Type Grade Stage
1 70 M Crescentic glomerulonephritis DLBCL High IV 6 Chemotherapy Yes/2 wk
2 79 M Hypertensive nephrosclerosis TCC Low 0 4 TURBT No/5 y
3 71 M Unknown TCC Low 0 6 TURBT Alive/2 y
4 34 M Reflux/obstructive uropathy
(congenital)
CIS High 0 13 TURBT Alive/6 y
5 60 M PCKD TCC High 0 8 TURBT Alive/2.5 y
6 24 M Reflux/obstructive uropathy
(congenital anomaly)
SCC High IV 20 Cystectomy þ bowel
resection
Yes/3 mo








High III 15 Pelvic exenteration þ
Radiotherapy
Alive/8 y 10 mo
9 76 M Renovascular disease TCC High IV 6 TURBT, unfit for
further therapy
Yes/3 wk
10 28 F Reflux/obstructive uropathy
(congenital anomaly)




11 80 F Analgesic Nephropathy TCC High I 4 TURBT No/11 mo
12 40 F PCKD TCC High IV 8 TAH/BSO þ cystectomy þ
transplant nephrectomy
Alive/5 y
13 57 M IgA nephropathy TCC High IV 7 Cystoprostatectomy þ
transplant nephrectomy
Alive/3 y
14 59 M Ischemic nephropathy SCC High III 1.6 Cystoprostatectomy þ
chemotherapy
Yes/11 mo
15 70 F ANCA vasculitis TCC High III 7 Anterior pelvic exenteration Alive/1 y 5 mo
Abbreviations: Adenoca, adenocarcinoma; CIS, carcinoma in situ; DLBCL, diffuse large B-cell lymphoma; ESKD, end-stage kidney disease; PCKD, polycystic kidney
disease; SCC, squamous cell carcinoma; TAH/BSO, total abdominal hysterectomy/Bilateral salpingo-oopherectomy; TCC, transitional cell carcinoma; TURBT, tran-
surethral resection of bladder tumor.
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Bladder cancer is the fourth most common incident cancer
among males in the United States, the United Kingdom,
and the Republic of Ireland. It is also the 9th most commonTable 2. Patients With Identifiable Risk Associations for Bladder
Cancer in Addition to Immunosuppression
Patient Risk Factor
1 Cyclophosphamide
2 Obstructive uropathy (TURP-treated BPH)
4 Reflux/obstructive uropathy (congenital neurogenic
bladder)
6 Reflux/obstructive uropathy, reconstructive urinary tract
surgery (prune belly syndrome)
7 Vesicoureteric reflux
8 Reflux/obstructive uropathy, reconstructive urinary tract
surgery (ectopia vesicae)
10 Reflux/obstructive uropathy, reconstructive urinary tract
surgery, self-intermittent catheterization (spina bifida)
11 Analgesic Nephropathy
13 BK virus nephropathy
14 Extensive smoking
15 Cyclophosphamide
Patient numbers correspond with those in Table 1.
Abbreviations: BPH, benign prostatic hyperplasia; TURP, transurethral
resection of the prostate.cancer among females in the United States and the 12th
most common for women in Ireland. Observational data
have shown not only worldwide increased bladder cancer
incidence in RTRs (11e32; Supplementary Appendix), but
also more aggressive disease with poorer outcomes when
compared with the general population [21,33]. The inci-
dence of bladder cancer in RTRs varies depending on the
population studied from 0.08% to 2.8%, which is 2e3 times
greater than in the general population. These findings are
consistent with our present case series. Excluding Chinese
populations, a male predominance is seen across all other
population groups; females tend to present with higher
stage tumors. With the exception of the study by Kamal et al
[17] illustrating a high prevalence of schistosomiasis related
squamous cell bladder cancer in the Egyptian population,
posttransplant bladder cancer cases reported in the litera-
ture are mostly transitional cell carcinoma (TCC) and the
vast majority of studies report exclusively TCC cases. Our
case series includes a patient with adenocarcinoma and
another with lymphoma of the bladder as well as 3 cases
with squamous cell carcinoma, which were reported in a
recent paper by Davis et al [34] on squamous cell bladder
cancer after diseased donor renal transplantation. Apart
from the increased incidence, we observed important
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Fig 1. Cumulative incidence of bladder cancer in renal trans-
plant recipients.
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in RTRs occurred at an earlier age; mean age was 56
compared with a mean age of 70 at the time of diagnosis in
the general population. The younger mean age of the
transplant population mitigates the significance of this large
age discrepancy. However, more disconcertingly, we found
that two thirds of those RTRs diagnosed with bladder
cancer had muscle invasive disease at diagnosis with a 1-year
overall survival of 60%. In the general Irish population,
25% of bladder cancer cases were classified as muscle
invasive (stages 2e4) throughout the study period; 35% were
superficial tumors and carcinoma in situ, and the remaining
40% were unstaged or classified as neoplasms of uncertain
behavior. The 1-year survival after diagnosis of bladder
cancer in the general population was 72%, notwithstanding
that these were older patients and bladder cancer was
reported to be the cause of death in approximately one half
of these patients only. Approximately 70% of those diag-
nosed with bladder cancer in the Irish general population
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Fig 2. Patient survival after bladder cancer diagnosis in kidney
transplant recipients.Traditional environmental risk factors associated with
bladder malignancy include smoking, radiation, occupa-
tional exposures, and, in the case of squamous cell
carcinoma, urinary schistosomiasis [35,36]. The post-
transplantation immunosuppression status of transplant
recipients is thought to result in impaired DNA repair
mechanisms and impaired protection against oncogenic
viruses, further increasing the risk for a variety of
neoplastic conditions, including bladder cancer. Although
a causal relationship has not been unequivocally proven,
human papillomavirus virus and the BK polyoma virus
have both been implicated in the pathogenesis of bladder
cancer [37e41]. High level expression of BK polyoma virus
large T antigen in tumor tissue, but not in the non-
neoplastic urothelium, suggest that BK polyoma virus
may play a role in the oncogenic pathway in the post-
transplantation setting. In this study, 2 of our patients had
biopsy proven condylomata acuminata, 1 before and 1
after diagnosis of bladder cancer; hence, a possible asso-
ciation of human papilloma virus infection, a less recog-
nized risk factor, with the development of their bladder
tumors. Both patients however had vesicoureteric reflux
and their bladder tumors were not analyzed for human
papillomavirus virus infection using polymerase chain re-
action. One of these patients had a neurogenic bladder, a
longstanding urethral stricture, and urethral warts before
diagnosis of a carcinoma in situ of bladder; and had biopsy
confirmed condyloma acuminatum from a urethral lesion
on follow-up 3 years later. The second patient had spina
bifida with an ileal conduit and-biopsy proven condyloma
accuminata from cervical and vulval lesions 2 and 5 years,
respectively, before the diagnosis of invasive squamous cell
bladder cancer.
The increased incidence of cancer of the urinary tract
and overall cancer risk in dialysis patients has been
demonstrated in previous observational studies [42e47].
Both dialysis-dependent patients and RTRs had a higher
proportion of muscle invasive bladder cancer and non-
urothelial bladder tumors than the general population in a
large, retrospective, US database analysis [21]. This implies
that factors related to the underlying renal pathology, such
as analgesic abuse, cyclophosphamide exposure, or uro-
genital disease, as well as the immune dysfunction and
nutritional deficiencies associated with uremia and dialysis
dependence, may contribute to the higher risk and poorer
outcomes in transplant recipients [41,46,48]. The risk of
bladder cancer has also been shown to be elevated in men
with a history of benign prostatic hyperplasia treated with
transurethral resection of prostate [49,50]. Therefore,
the status of reaching end-stage kidney disease, underlying
genetic, congenital, developmental, and environmental
factors, including those related to the primary renal disease,
may all interact with superimposed immunologic manipu-
lation in a transplant recipient, amounting to a higher
cancer risk profile.
Much of the literature on posttransplantation bladder
malignancy originates from China, where a high incidence
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reported. Kidney and bladder cancers were found to be the
most common posttransplant malignancies in Chinese kid-
ney transplant recipients in Taiwan [29], and bladder cancer
had the highest SIR among solid organ malignancies in the
Hong Kong renal registry [31]. Exposure to Chinese herbs
and arsenic in underground water sources are among the
additional endemic risk factors that are implicated in the
higher prevalence of urothelial cancer seen in these pop-
ulations [51,52]. A pattern of female predominance and a
higher incidence of synchronous and isolated upper tract
involvement were seen in the Chinese population [15,30,31].
A protocol of screening for urothelial cancer including
bladder tumors in these higher risk populations was pre-
sented in the Congress of the Asian Society of Trans-
plantation in 2005. The accelerated rate of diagnosis of
these cancers in the transplant population of this region in
the last few years may be partially attributed to detection of
early lesions owing to enhanced and intensive screening of
asymptomatic patients [53].
In general, the treatment of bladder malignancy in
transplant recipients is broadly similar to that instituted in
nontransplant patients, with preservation of the renal
allograft reported in most case series. Pertinent manage-
ment issues that arise in and are unique to solid organ
transplant recipients include concomitant management of
immunosuppression and the consequences and additional
morbidity burden of loss of graft function. The use of
adjuvant intravesical bacillus Calmette-Guérin for none
muscle-invasive bladder cancer is controversial in trans-
planted patients but has been reported to be successful with
and without prophylactic anti mycobacterial cover [54,55].
Fatal disseminated mycobacterial infection has been re-
ported after intravesical bacillus Calmette-Guérin in
immunosuppressed patients [56,57]. Prolonged patient and
allograft survivals have been demonstrated after radical
surgery for bladder cancer in transplant recipients in our
series and other reports. Clearly, however, the aim should
be earlier diagnosis of superficial tumors. The discordance
between the intensity of medical follow-up that these pa-
tients are committed to and the late detection of bladder
malignancy calls for concern and urges improvements in
clinical practice for earlier identification and treatment of
these patients. The finding of residual microscopic hema-
turia owing to intrinsic or structural renal disease in native
kidneys can be a source of confusion and delayed diagnosis.
On the other hand, anuric patients on dialysis may present
at a later stage owing to absence of frank hematuria, the
commonest presenting symptom of bladder malignancy, and
for the same reason may potentially be transplanted during
an early stage of an undiagnosed bladder tumor.
Enhanced urologic screening has been advocated by
various authors for early detection of urothelial malignancy
in transplant recipients [15,16,18,20,21,29,31,58]. However,
owing to lack of adequate evidence and cost-effectiveness
studies as well as interpopulation differences in risk fac-
tors, tumor characteristics, incidence, and outcomes, thereis no consensus of a universally accepted, risk-adapted sur-
veillance protocol, and specific screening strategies for
selected patient groups have seldom been proposed. In
addition to these recommendations for considering pre-
transplant cystoscopy in patients with a history of analgesic
nephropathy or cyclophosphamide exposure [3e6], similar
screening of heavy smokers, those with end-stage kidney
disease owing to toxic, infectious, or obstructive uropathies,
and those with a history of exposure to industrial carcino-
gens or schistosomiasis has been recommended as part of
the pretransplantation urologic evaluation [58]. Surveillance
posttransplantation raises more controversy with regard to
the optimal screening strategy and perceived potential
benefit versus long-term cost considerations. Although some
authors suggested screening within the first 4e5 years after
transplantation [21,59], the risk period may be extended to
considerably longer durations. Bladder cancer occurred at a
significantly later stage posttransplantation in our study
population, 8 years on average as opposed to 5e6 years in
other studies [13,21,31]. Moreover, we have diagnosed
bladder cancer at 20 years posttransplantation, arguing for
the need for ongoing monitoring and surveillance. In the
Asian populations, a high incidence of synchronous upper
tract urothelial carcinomas, an association with use of Chi-
nese herbs and a much higher overall incidence compared
with Western countries, mandates unique and more
vigorous screening programs aiming at early detection of
urothelial cancer in transplant recipients [15,20,30,60].
The development of an effective and cost-efficient, risk-
tailored screening strategy for pretransplant and posttrans-
plant bladder cancer is a challenging prospect, but of
significant importance given that early stage disease is usu-
ally curable. A pragmatic approach is required in the
absence of definitive evidence to guide recommendations
for surveillance. In a relatively low-risk Western population,
current evidence does not justify routine screening of
transplant candidates and recipients for urologic cancer;
however, increased vigilance must be exercised, particularly
in high-risk patients, so that appropriate investigation of
microscopic hematuria is instigated without delay. In addi-
tion to the standard indications for cystoscopic examination,
such as unexplained hematuria, recurrent urinary tract in-
fections, obstructive urinary symptoms, and surveillance for
recurrent urothelial cancer, it seems reasonable to adopt a
policy of high index of clinical suspicion and low threshold
for cystoscopy in patients with any of the risk factors iden-
tified in this study. The anticipated improvements in prog-
nosis for patients diagnosed with posttransplantation
bladder cancer over time may be informative with regard to
the cost considerations and modifications needed for future
screening strategies.
To our knowledge, this is the first study to highlight the
likely augmented risk of bladder cancer in kidney transplant
recipients with underlying genitourinary abnormalities
compared with the general renal transplant population. Our
institution benefits from being the national renal transplant
center where all kidney transplants in Ireland are performed,
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ical data. We also cross-linked our data with the national
cancer registry database to calculate the SIR. The limi-
tations of this study include those relating to the retro-
spective nature of registry data analysis where some
relevant information, such as background environmental
risk associations, may be missing and cancer incidence
may be underreported. Because the inclusion periods of
the 2 registries are discordant, the NRTR predating the
NCRI by 30 years, the 0.48% incidence of bladder cancer
found in RTRs is likely to represent an underestimate of
the true incidence as any transplant recipients diagnosed
with bladder cancer between 1964 and 1994 were missed.
That being said, the incidence of bladder cancer in RTRs
was found to be higher in comparison with the Irish
general population with a SIR of 2.5; the true incidence
and corresponding SIR could be higher. The relatively
low incidence of bladder cancer contributes to a reduction
in the statistical power of the study. The presence of a
preexisting tumor could not be excluded in 1 patient who
was diagnosed only 2 months after transplantation during
routine cystoscopic removal of a ureteric stent.
In conclusion, RTRs have a 2.5-fold increased risk of
bladder malignancy compared with the general population
in Ireland, with a high rate of aggressive tumors and cancer-
related mortality. As renal allografts in the era of current
immunosuppression survive longer, posttransplantation
incidence of bladder cancer may rise. Preexisting genito-
urinary abnormalities, toxic nephropathies, and cyclophos-
phamide exposure seem to confer additional risk. The issue
of screening posttransplantation is difficult to resolve given
the low incidence of bladder cancer and further research is
needed before routine risk adapted cystoscopic surveillance
can be recommended. Vigilance in detecting and evaluating
new, unexplained, microscopic and macroscopic hematuria,
particularly in high-risk patients, is imperative to facilitate
earlier diagnosis.
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Appendix. Recent Studies Including Reports of Primary Bladder Cancer After Renal Transplantation*








Survival of PatientsRenal Grafts RTRs Patients % TCC/CIS
Wang H-B et al 2002, Taiwan [11] 320 2.1 8§ 100 2.5% 100% at 1 y
Kao Y-L et al 2003 Taiwan [12] 670 NR 15§ 100 2.24% 73% at 1 y
Master VA et al, 2004 [13] 6288 8.9k 5 100 0.08% 60% at 1 y
Master VA et al 2004, USA (UNOS) [13] 129,238 5.2 31 NR 0.024% NR
Master VA et al, 2004, CTTR [13] NR 6.4 135 NR NR NR
Liao C-H et al, 2004, Taiwan [14] 663 NR 6§ 100 0.9% NR
Wu M J et al, 2004 Taiwan [15] 730 NR 20§ 100 2.74% NR
Diller R et al, 2005 Germany [16] 2068 1804 7.3 6§ 100 0.33% 80% at 1 y 40% at 5 y
Kamal M et al, 2007, Egypt [17] 1865 1865 9.4 7 57 0.37% NR
Besarani et al, 2007 UK (UKTR) [18] 10,847 NR 48 NR 0.44% NR
Villeneuve et al, 2007, Canada
(CORR, CCR) [19]
11,155 NR 24 NR 0.22% (2.0) NR
Li X-B et al, 2008 China [20] 1735 1669 3.6 18§ 100 1.08% 100% at 1 y
Ehdaie et al, 2009, USA
(SEER-Med) [21]
97,942 5.2 58 83 0.06% NR
Einollahi et al, 2009, Iran [22] 5532 NR 7 100 0.13% NR
Elkentaoui et al, 2010, France [23] 1350 7.3 5 100 0.37% 60% at 5 y
Tsaur et al, 2010 Germany [24] 1990 6.9 18 100 0.90% 85% at 1 y¶ 67% at 5 y¶
Melchior et al, 2011, Germany [25] 802 2.3 6 100 0.75% NR
Hwang et al, 2011, Korea [26] 1695 6.6 8 NR 0.47% NR
Cox J et al, 2011 USA [27] 5920 5.4 8 100 0.13% NR
Tomaszewski et al 2011, USA [28] 2925 NR# 8 100 0.27% NR
Li W-H et al, 2012 Taiwan (NHIRD) [29] 4716 NR 72 NR 1.53% (42.9) NR
Chiang et al, 2012, Taiwan [30] 770 NR 22§ 100 NR** NR
Cheung et al, 2012, Hong Kong [31] 4895 4674 4.8 12§ NR 0.26% (8.2) NR
Rogers et al, 2012, UK [32] 1647 5.9 8 100 0.48% 83% at 5 y 72% at 10 y
Abbreviations: CCR, Canadian Cancer Registry; CORR, Canadian Organ Replacement Registry; CTTR, Cincinnati Transplant Tumor Registry; NHIRD, National
Health Insurance Research Database in Taiwan; NR, not reported (intervals to diagnosis and death in series that include patients with upper urinary tract TCC only are
not included unless they have reported those intervals for the subset of patients with bladder cancer); RTRs, renal transplant recipients; SEEReMed, Surveillance,
Epidemiology and End Results- Medicare database; SIR, standardized incidence ratio; ratio of the observed-to-expected number of incident cancers; TCC/CIS,
transitional cell carcinoma/carcinoma in situ; UKTR, United Kingdom Transplant Registry; UNOS, United Network for Organ Sharing.
*Studies since 2000 including >3 renal transplant recipients diagnosed with bladder cancer included.
†Most papers reported the number of renal transplant recipients (RTRs), although some papers reported the number of renal transplants with or without the number
of RTRs.
‡Incidence per patients.
§Series include patients with synchronous upper tract tumors.
kAfter excluding 1 patient in whom TCC developed 33 years after transplantation, mean time to diagnosis was 2.8 years.
¶Tumor-specific survival reported for 20 patients in total including those with upper tract transitional cell carcinoma.
#Mean interval of 39 months between transplantation and bladder cancer diagnosis was recorded for a series including 3 additional patients who received liver
transplants in this paper.
**The reported incidence of all urothelial cancers including those in the kidney and/or ureter only was 4.55% of renal transplantations. Only 7 patients (20%) had
bladder cancer alone. All cancers were transitional cell carcinomas with a sarcomatoid variant in 1 case.
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